Welcome to our dedicated page for N2OFF news (Ticker: NITO), a resource for investors and traders seeking the latest updates and insights on N2OFF stock.
N2OFF, Inc. (NASDAQ: NITO) generates news across several distinct areas, reflecting its profile as a clean tech and cleantech company with activities in renewable energy, agri-tech, and biotechnology. Company announcements describe N2OFF as mainly engaged in EU-based solar assets using a Ready to Build (RTB) business model, while also owning MitoCareX Bio Ltd., a drug discovery company targeting cancer therapeutics through the mitochondrial SLC25 protein family, and controlling a majority stake in Save Foods Ltd., an Israeli post-harvest treatment company focused on pathogen contamination in fruits and vegetables.
News updates frequently cover renewable energy milestones, including progress on solar photovoltaic and battery energy storage projects in European Union countries through partnerships with Solterra Renewable Energy Ltd. These releases highlight permitting developments, funding arrangements, and changes in project economics for flagship projects in markets such as Germany and Italy.
Another stream of coverage focuses on biotech and precision oncology activity at MitoCareX. N2OFF reports on scientific advances related to mitochondrial SLC25 transport proteins, the use of the MITOLINE™ algorithm for 3D protein modeling and virtual screening, and progress toward identifying hit compounds and potential preclinical candidates for hard-to-treat cancers.
Investors following NITO news will also see corporate and capital markets updates, such as the completion of the MitoCareX acquisition, reverse stock split implementation, Nasdaq minimum bid price compliance, and agreements involving the planned transfer of N2OFF’s majority stake in Save Foods to Voice Assist, Inc. Together, these categories of news provide insight into how N2OFF manages its multi-segment portfolio across clean energy, agri-tech, and biotech drug discovery.
Summary not available.
Summary not available.